Press time:2020-12-23From:CR Pharma [Font:BigMediumSmall]
On December 22, 2020, the signing ceremony between CR Double-Crane and Shandong Haike was held in Dongying, Shandong, and the “Dongying Tiandong Pharmaceutical Equity Transfer Agreement” was formally signed.
At the ceremony, Chairman of China Resources Double-Crane Pharmaceuticals, Feng Yi gave a speech and introduced the project. Chairman of Haike Group Board, Yang Xiaohong expressed his prospect of the cooperation. President of Shandong Haike Group, Zhang Zaizhong, and President of China Resources Double-Crane Pharmaceuticals, Yu Shunting signed the cooperation agreement.
Dongying Tiandong Pharmaceutical Co., Ltd. was established in 1992. The company specializes in low molecular weight heparin raw materials. The main products include heparin sodium, enoxaparin sodium, dalteparin sodium, natraheparin calcium, etc. The products are exported to more than 40 countries and regions around the world. The company is committed to providing customers with quality products and services, and continuously improving the production quality management system. It has successively passed a series of domestic and international pharmaceutical administration certifications, including China GMP certification, EU COS certification, US FDA certification and Brazil. Official certification by Sweden, Mexico, Turkey and other countries.
On December 17, China Resources Double-Crane issued an announcement that according to the company's overall strategic plan, in order to further enrich the products in the field of cardiovascular and cerebrovascular anticoagulation and obtain a technical platform in the field of anticoagulation, the company uses its own funds to acquire 38.75% of Dongying Tiandong Pharmaceutical Co., Ltd., at a price of 341 million yuan. The management of the company is responsible for organizing and implementing the relevant work of this equity acquisition project.
